Status:
COMPLETED
Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients
Lead Sponsor:
SkyePharma AG
Conditions:
Asthma
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The primary purpose was to evaluate the efficacy of SKP FlutiForm HFA MDI compared to placebo or fluticasone and formoterol administered concurrently or alone in asthma patients.
Eligibility Criteria
Inclusion
- Subjects with documented history of mild to moderate asthma currently taking a stable dose of inhaled corticosteroid
Exclusion
- Smoking history within the last 12 months
- No history of respiratory tract infection within 4 weeks
- No history or evidence of any clinically significant disease or abnormality
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2005
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00830102
Start Date
October 1 2004
End Date
January 1 2005
Last Update
June 23 2011
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational site
Belfast, Ireland
2
Investigational site
Derbyshire, United Kingdom
3
Investigational site
London, United Kingdom
4
Investigational site
Manchester, United Kingdom